An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer
TAIPEI, Sept. 13, 2022 /PRNewswire/ — AnBogen Therapeutics, a clinical-stage biotech firm designing and growing precision oncology therapies to enhance the lifetime of sufferers, proclaims at present that U.S. Food and Drug Administration (FDA) has authorized an investigational new drug (IND) protocol modification for its section Ib/II trial of ABT-101, an orally administered, irreversible, mutant selective tyrosine kinase inhibitor concentrating on oncogenic mutations of HER2 Exon20 insertion expressed in non-small cell lung most cancers (NSCLC).
“We are pleased to receive approval from the FDA on the protocol amendment, and continue to drive ABT-101 clinical development program forward. With the mission in mind, we want to make impact to transform the treatment for patients with non-small cell lung cancer harboring exon 20 insertions (e20i) in HER2,” stated John Tsu-An Hsu, Ph.D, Founder and Chief Executive Officer of Anbogen Therapeutics. “We look forward to working closely with FDA and all of our investigators as we enroll and dose the patients with non-small cell lung cancer (NSCLC). ABT-101 demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development, and it meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions (e20i) in HER2.”
ABT-101
ABT-101 is a potent small molecule kinase inhibitor towards a number of oncogenic kinases together with epidermal development issue receptor (EGFR), and human epidermal development issue receptor 2 (HER2, often known as ERBB2). Approximately 10% to 12% of EGFR mutations and about 2% to 4 % of HER2 mutations in NSCLC are current in exon 20. Importantly, 90% of HER2 mutations in NSCLC are exon 20 mutations. It is estimated that the worldwide annual affected person inhabitants is bigger than 56,000 who harbor HER2 exon insertion mutation. In the pre-clinical pharmacological research, Anbogen has demonstrated that ABT-101 has superior selectivity towards HER2 e20i mutation and considerably inhibits the expansion of tumor harboring HER2-e20i.
About Anbogen Therapeutics
Anbogen Therapeutics is a clinical-stage biotech firm designing and growing precision oncology therapies to enhance the lifetime of sufferers. Founded by a gaggle of remarkable scientists from National Health Research Institute, essentially the most prestigious medical analysis institute in Taiwan, Anbogen Therapeutics is dedicated to convey hole between analysis and scientific improvement, and devoted to creating breakthrough science that meaningfully modifications lifetime of sufferers. With the imaginative and prescient to ship the best-in-class therapies, our collective expertise in medicinal chemistry, most cancers biology, drug discovery and scientific improvement, which significantly allow the event of differentiated pipeline within the area of precision oncology.
CONTACT: Anbogen Therapeutics, [email protected]
